Tesamorelin Dosage: Reported Research Ranges
Reported in research: 1–2 mg once daily (subcutaneous) in published human trials, most often 2 mg; practitioner protocols report 1–2 mg daily. Sources broadly agree.
Dosing Protocols Research · Peptide dosage chart · What is Tesamorelin? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| 2 mg once daily, subcutaneous (most trials); 1 mg daily in one trial | Human trial (published study) | Human: randomized controlled trials |
| 1–2 mg daily (one source lists 5 days on, 2 days off) | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| 1 mg at night | Dr. Trevor reports | Practitioner report (not a clinical trial) |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials in our library
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors · PubMed 38905488
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial · PubMed 31611038
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial · PubMed 25038357
- Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging · PubMed 23689947
- Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial · PubMed 23015655
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension · PubMed 20101189
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation · PubMed 18690162
- Metabolic effects of a growth hormone-releasing factor in patients with HIV · PubMed 18057338
FAQ
What Tesamorelin dosage is reported in research?
Reported in research: 1–2 mg once daily (subcutaneous) in published human trials, most often 2 mg; practitioner protocols report 1–2 mg daily. Sources broadly agree.
Is there human-trial evidence for Tesamorelin dosing?
Yes. Published randomized trials in our study library report the amounts in the table above.
Why do the reported Tesamorelin amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a Tesamorelin amount into syringe units?
The PeptideWhiz calculator for Tesamorelin converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.